Mesenchymal Stem/stromal Cells: Dedicator to Maintain Tumor Homeostasis

Overview

Journal Hum Cell

Publisher Springer

Specialty Cell Biology

Date 2024 Nov 28

PMID 39607530

Authors

Juncun Yao

Li Sun

Feng Gao

Wei Zhu

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stem/stromal cells （MSCs） act as a factor in tumor recurrence after drug treatment with their involvement observed in various cancer types. As a constituent of the tumor microenvironment (TME), MSCs not only provide support to tumor growth but also establish connections with diverse cell populations within the TME, serving as mediators linking different tumor-associated components. MSCs play an important role in maintaining tumor progression due to their stem cell properties and remarkable differentiation capacity. Given the intensification of tumor research and the encouraging results achieved in recent years，the aim of this article is to investigate the supportive role of MSCs in tumor cells as well as in various cellular and non-cellular components of the tumor microenvironment. Furthermore, the article shows that MSCs do not have a specific anatomical ecological niche and describes the contribution of MSCs to the maintenance of tumor homeostasis on the basis of homing, plasticity and tumor-forming properties. By elucidating the critical roles of different components of TME, this study provides a comprehensive understanding of tumor therapy and may offer new insights into defeating cancer.

References

Belli C, Trapani D, Viale G, DAmico P, Duso B, Della Vigna P . Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018; 65:22-32. DOI: 10.1016/j.ctrv.2018.02.004. View

Borriello L, Nakata R, Sheard M, Fernandez G, Sposto R, Malvar J . Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res. 2017; 77(18):5142-5157. PMC: 5600847. DOI: 10.1158/0008-5472.CAN-16-2586. View

Zhang G, Guo C, Wang Y, Zhang X, Liu S, Qu W . FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma. J Hematol Oncol. 2022; 15(1):177. PMC: 9798557. DOI: 10.1186/s13045-022-01395-0. View

Guo K, Schafer R, Paul A, Gerber A, Ziemer G, Wendel H . A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells. 2006; 24(10):2220-31. DOI: 10.1634/stemcells.2006-0015. View

Stratford E, Castro R, Wennerstrom A, Holm R, Munthe E, Lauvrak S . Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential. Clin Sarcoma Res. 2012; 1(1):8. PMC: 3351708. DOI: 10.1186/2045-3329-1-8. View

Atiya H, Frisbie L, Pressimone C, Coffman L . Mesenchymal Stem Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1234:31-42. DOI: 10.1007/978-3-030-37184-5_3. View

Desi N, Teh V, Tong Q, Lim C, Tabatabaeian H, Chew X . MiR-138 is a potent regulator of the heterogenous MYC transcript population in cancers. Oncogene. 2021; 41(8):1178-1189. PMC: 8856960. DOI: 10.1038/s41388-021-02084-x. View

Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J . Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res. 2018; 37(1):324. PMC: 6307162. DOI: 10.1186/s13046-018-0965-2. View

Leonard N, Corry S, Reidy E, Egan H, OMalley G, Thompson K . Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signaling. iScience. 2024; 27(9):110701. PMC: 11416555. DOI: 10.1016/j.isci.2024.110701. View

10.

Li M, Zheng R, Liu Z, Zhang P, Zhu T, Xin X . Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma. Front Immunol. 2025; 15():1502936. PMC: 11703830. DOI: 10.3389/fimmu.2024.1502936. View

10.

Wang X, Zhang L, Zhang Y, Li J, Xu W, Zhu W . Distinct types of VHHs in Alpaca. Front Immunol. 2024; 15:1447212. PMC: 11588638. DOI: 10.3389/fimmu.2024.1447212. View

11.

Verstappe J, Berx G . A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer. Semin Cancer Biol. 2023; 90:15-28. DOI: 10.1016/j.semcancer.2023.02.001. View

12.

Tang X, Chen M, Li X, Lu H, Zhang X, Li Y . A Mechanistic Approach on Perception Mode of ABA Receptors (PYLs) to Novel Opabactin Analogues. J Agric Food Chem. 2024; 72(48):26967-26982. DOI: 10.1021/acs.jafc.4c07265. View

12.

Qin Y, Wang X, Dong H, Ye T, Du N, Zhang T . Plant Growth-Promoting Rhizobacteria HL14-3 Inoculation Enhances Drought Tolerance in Cucumber by Triggering Abscisic Acid-Mediated Stomatal Closure. J Agric Food Chem. 2024; 73(1):260-272. DOI: 10.1021/acs.jafc.4c09421. View

13.

Ivanovski S, Han P, Peters O, Sanz M, Bartold P . The Therapeutic Use of Dental Mesenchymal Stem Cells in Human Clinical Trials. J Dent Res. 2024; 103(12):1173-1184. PMC: 11562285. DOI: 10.1177/00220345241261900. View

14.

Lee Y, Lin S, Yu G, Zhu M, Song J, Rivera K . Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene. 2021; 41(6):757-769. PMC: 8818031. DOI: 10.1038/s41388-021-02131-7. View

15.

Saraiva L, Silva R, Pereira G, Goncalves J, Corte-Real M . Specific modulation of apoptosis and Bcl-xL phosphorylation in yeast by distinct mammalian protein kinase C isoforms. J Cell Sci. 2006; 119(Pt 15):3171-81. DOI: 10.1242/jcs.03033. View

16.

Hegyi B, Sagi B, Kovacs J, Kiss J, Urban V, Meszaros G . Identical, similar or different? Learning about immunomodulatory function of mesenchymal stem cells isolated from various mouse tissues: bone marrow, spleen, thymus and aorta wall. Int Immunol. 2010; 22(7):551-9. DOI: 10.1093/intimm/dxq039. View

17.

Ribeiro A, Laranjeira P, Mendes S, Velada I, Leite C, Andrade P . Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther. 2014; 4(5):125. PMC: 3854702. DOI: 10.1186/scrt336. View

18.

Zhao P, Gao C, Dykema K, Furge K, Feng Z, Cao B . Repeated hepatocyte growth factor neutralizing antibody treatment leads to HGF/SF unresponsiveness in human glioblastoma multiforme cells. Cancer Lett. 2009; 291(2):209-16. DOI: 10.1016/j.canlet.2009.10.014. View